September 28, 2026

Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169

Vyriad’s Phase 1 VV169 study will evaluate whether a targeted lentiviral vector can generate BCMA-directed CAR T cells directly inside patients with multiple myeloma.